Skip to main content

Zimmer NexGen MDL Nearing Settlement with a Confidential Deal

Zimmer NexGen MDL Nearing Settlement with a Confidential Deal

Zimmer NexGen MDL Nearing Settlement with a Confidential Deal

Introduction

Zimmer NexGen knee implant multidistrict litigation may end soon as counsel heading a group of consumers confirmed about a final confidential settlement for nearly 300 lawsuits.

The counsel for the plaintiffs told the U.S. District Judge Rebecca Pallmeyer, the 7-year ongoing litigation would be resolved soon after minor administrative task completion. The undisclosed amount if approved would be divided among plaintiffs who filed lawsuits against Zimmer claiming complications occurred due to the defectively designed knee implant.

Zimmer NexGen knee implant lawsuits were consolidated in 2011, as a part of MDL 2272  (In Re: Zimmer NexGen Knee Implant Products Liability Litigation) in the Northern District of Illinois.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest News

title demo for news

Categories: Settlements

created dropdown in quarterly-results page in localy, and explore all the component codes 

Zantac Settles 4,000 Lawsuits in U.S. Courts

Categories: General

Sanofi has announced a settlement agreement regarding approximately 4,000 Zantac cancer lawsuits filed in state courts across the country.

Valsartan Recall Lawsuit Set for Trial

Categories: General

Years after the initiation of Valsartan recalls, the U.S. District Judge overseeing lawsuits filed by individuals harmed by tainted versions of…

Our Legal Drafting Services    
start @ $25 per hour.